Tag Archives: Industry Analysis

The Good, the Bad, and the Ugly for Biotech IPOs

2012-11-12-Technology-vs-HC-IPOs-btn

The troubles in the biotech IPO market are complicated to explain to industry outsiders. They read about new biotechs debuting on the public market, but also hear bankers, VCs, and CEOs complaining about how the IPO window never really opened after 2008. The reality is that we are seeing positive developments and negative trends simultaneously. On the bright side, the cumulative number of IPOs is holding up. The recent pace of biotech IPOs mimics what Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , ,

BIO Investor Forum: The New Kids on the Biotech Block

desert

Where should biotech start-ups look for funding in the venture capital desert that is becoming the new normal? The panel The New Kids on the Biotech Block: Trends in Early-Stage Financing kicked off the 11th Annual BIO Investor Forum and focused on non-traditional early-stage investors and deal structures. Moderated by Jeron Eaves, a senior practice executive with Campbell Alliance, the panel highlighted companies that have secured financing from creative sources, like patient advocacy groups and venture Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

How does the NBI perform in the last quarter of the year?

YTD-10-08-2012

Does the NASDAQ Biotech Index (NBI) outperform the broader market in the last three months of the year, or underperform? The NBI tends to be up in the 4th quarter, but a lot of that has to do with the overall market, not the biotechs. Here are the returns for the last quarter of the year for the last 20 years: (source: Factset) When looking directly at overall performance, biotech and the broader market have had good Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Recommended Reading from BIOtechNOW

Partnering Meetings

We hope the dust has settled from Boston’s International Convention, and you’re ready for a busy fall schedule! Here’s just a quick post on some recent articles that have been published on BIOtechNOW that’s worth a read. 2012 Fall Event Preview – A recap of BIO’s upcoming BD events, among others. 2012 BIO Convention in China: Highlighting Cross-Border Partnering in Biotechnology – Take a deeper look at the 2nd Annual BIO China event. We’re also Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Indices, IPOs, and New Drug Approvals – Update July 6th 2012

Index-Perfomance-June-2012-thumb

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued on its path of outperforming the market, up 24.6 percent and increasing its Year-to-Date (YTD) lead over the S&P 500 which is up 8.3 percent. The Amex Biotech Index (BTK) closed out June up a hefty 34.6 percent YTD: 2. IPOs: Tesaro, Inc. (TSRO) was June’s sole U.S. IPO, raising $81M.  The company was formed just two years ago and has aggressively in-licensed cancer treatments from Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,